AG˹ٷ

STOCK TITAN

[Form 4] VolitionRX Limited Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

VolitionRx Ltd. (VNRX) � Form 4 filing

Chief Commercial Officer Gael Forterre reported a single Code F transaction on 1 Aug 2025, reflecting shares surrendered to the company to cover taxes upon settlement of 6,690 restricted stock units received in lieu of cash compensation. 2,766 common shares were withheld at an implied price of $0.64 and therefore cancelled; no open-market sale occurred.

Following the withholding, Forterre’s holdings stand at 156,700 directly-owned shares. He also reports 5,000 shares held indirectly by his spouse and 32,500 shares managed through Armorica Partners, LLC, over which he exercises voting and dispositive control. The filing represents routine administrative tax withholding and does not signal a change in insider ownership intent or corporate outlook.

VolitionRx Ltd. (VNRX) � Deposito Form 4

Il Chief Commercial Officer Gael Forterre ha comunicato una singola transazione di Codice F il 1 agosto 2025, relativa a azioni consegnate alla società per coprire le tasse al momento della liquidazione di 6.690 unità azionarie vincolate ricevute in sostituzione della retribuzione in contanti. Sono state trattenute 2.766 azioni ordinarie a un prezzo implicito di 0,64 $ e pertanto annullate; non è avvenuta alcuna vendita sul mercato aperto.

Dopo la trattenuta, le partecipazioni di Forterre ammontano a 156.700 azioni di proprietà diretta. Riporta inoltre 5.000 azioni detenute indirettamente da sua moglie e 32.500 azioni gestite tramite Armorica Partners, LLC, sulle quali esercita controllo di voto e disposizione. Il deposito rappresenta una normale trattenuta fiscale amministrativa e non indica un cambiamento nell’intento di proprietà interna o nelle prospettive aziendali.

VolitionRx Ltd. (VNRX) � Presentación del Formulario 4

El Director Comercial Gael Forterre reportó una única transacción Código F el 1 de agosto de 2025, que refleja acciones entregadas a la empresa para cubrir impuestos tras la liquidación de 6,690 unidades de acciones restringidas recibidas en lugar de compensación en efectivo. Se retuvieron 2,766 acciones comunes a un precio implícito de $0.64 y por ello fueron canceladas; no se realizó ninguna venta en el mercado abierto.

Tras la retención, las participaciones de Forterre ascienden a 156,700 acciones de propiedad directa. También reporta 5,000 acciones mantenidas indirectamente por su cónyuge y 32,500 acciones gestionadas a través de Armorica Partners, LLC, sobre las cuales ejerce control de voto y disposición. La presentación representa una retención fiscal administrativa rutinaria y no indica un cambio en la intención de propiedad interna ni en la perspectiva corporativa.

VolitionRx Ltd. (VNRX) � Form 4 제출

최고상업책임� Gael Forterre2025� 8� 1� 단일 코드 F 거래� 보고했으�, 이 현금 보상 대� 받은 6,690개의 제한주식 단위 정산 � 세금 납부� 위해 회사� 주식� 반납� 것을 반영합니�. 2,766주의 보통�가 암묵� 가� $0.64� 원천징수되어 취소되었으며, 공개 시장 매도� 없었습니�.

원천징수 � Forterre� 직접 소유 주식은 156,700�입니�. 또한 배우자가 간접 보유� 5,000�Armorica Partners, LLC� 통해 관리되� 32,500�� 보고하며, 이들 주식� 대� 의결� � 처분 권한� 행사합니�. 이번 제출은 일상적인 세금 원천징수 절차�, 내부� 소유 의도� 회사 전망� 변화를 의미하지 않습니다.

VolitionRx Ltd. (VNRX) � Dépôt du Formulaire 4

Le Directeur Commercial Gael Forterre a déclaré une seule transaction Code F le 1er août 2025, correspondant à des actions remises à la société pour couvrir les taxes lors du règlement de 6 690 unités d’actions restreintes reçues en lieu et place d’une rémunération en espèces. 2 766 actions ordinaires ont été retenues à un prix implicite de 0,64 $ puis annulées ; aucune vente sur le marché ouvert n’a eu lieu.

Après cette retenue, les avoirs de Forterre s’élèvent à 156 700 actions détenues directement. Il déclare également 5 000 actions détenues indirectement par son conjoint et 32 500 actions gérées via Armorica Partners, LLC, sur lesquelles il exerce un contrôle de vote et de disposition. Ce dépôt représente une retenue fiscale administrative courante et ne signale aucun changement dans l’intention de détention des initiés ni dans les perspectives de l’entreprise.

VolitionRx Ltd. (VNRX) � Form 4 Einreichung

Chief Commercial Officer Gael Forterre meldete am 1. August 2025 eine einzelne Code-F-Transaktion, bei der Aktien an das Unternehmen zurückgegeben wurden, um Steuern bei der Abwicklung von 6.690 eingeschränkten Aktieneinheiten zu begleichen, die anstelle von Barvergütung erhalten wurden. 2.766 Stammaktien wurden zu einem impliziten Preis von 0,64 $ einbehalten und somit storniert; ein Verkauf am offenen Markt fand nicht statt.

Nach der Einbehaltung hält Forterre 156.700 direkt besessene Aktien. Zudem berichtet er über 5.000 Aktien, die indirekt von seiner Ehefrau gehalten werden, sowie 32.500 Aktien, die über Armorica Partners, LLC verwaltet werden, über die er Stimm- und Verfügungsrechte ausübt. Die Einreichung stellt eine routinemäßige administrative Steuerabführung dar und signalisiert keine Änderung der Insider-Besitzabsicht oder der Unternehmensperspektive.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine tax-withholding; insider retains sizeable stake, no market sale � immaterial to valuation.

The Code F transaction merely offsets payroll taxes due on the vesting of 6,690 RSUs, resulting in 2,766 shares being returned to the treasury at $0.64. Forterre still controls roughly 194k shares (direct+indirect), indicating continued alignment with shareholders. Because no cash proceeds were realized and the share count impact is de minimis, the filing carries neutral information value for investors and should not materially affect liquidity, float, or sentiment.

VolitionRx Ltd. (VNRX) � Deposito Form 4

Il Chief Commercial Officer Gael Forterre ha comunicato una singola transazione di Codice F il 1 agosto 2025, relativa a azioni consegnate alla società per coprire le tasse al momento della liquidazione di 6.690 unità azionarie vincolate ricevute in sostituzione della retribuzione in contanti. Sono state trattenute 2.766 azioni ordinarie a un prezzo implicito di 0,64 $ e pertanto annullate; non è avvenuta alcuna vendita sul mercato aperto.

Dopo la trattenuta, le partecipazioni di Forterre ammontano a 156.700 azioni di proprietà diretta. Riporta inoltre 5.000 azioni detenute indirettamente da sua moglie e 32.500 azioni gestite tramite Armorica Partners, LLC, sulle quali esercita controllo di voto e disposizione. Il deposito rappresenta una normale trattenuta fiscale amministrativa e non indica un cambiamento nell’intento di proprietà interna o nelle prospettive aziendali.

VolitionRx Ltd. (VNRX) � Presentación del Formulario 4

El Director Comercial Gael Forterre reportó una única transacción Código F el 1 de agosto de 2025, que refleja acciones entregadas a la empresa para cubrir impuestos tras la liquidación de 6,690 unidades de acciones restringidas recibidas en lugar de compensación en efectivo. Se retuvieron 2,766 acciones comunes a un precio implícito de $0.64 y por ello fueron canceladas; no se realizó ninguna venta en el mercado abierto.

Tras la retención, las participaciones de Forterre ascienden a 156,700 acciones de propiedad directa. También reporta 5,000 acciones mantenidas indirectamente por su cónyuge y 32,500 acciones gestionadas a través de Armorica Partners, LLC, sobre las cuales ejerce control de voto y disposición. La presentación representa una retención fiscal administrativa rutinaria y no indica un cambio en la intención de propiedad interna ni en la perspectiva corporativa.

VolitionRx Ltd. (VNRX) � Form 4 제출

최고상업책임� Gael Forterre2025� 8� 1� 단일 코드 F 거래� 보고했으�, 이 현금 보상 대� 받은 6,690개의 제한주식 단위 정산 � 세금 납부� 위해 회사� 주식� 반납� 것을 반영합니�. 2,766주의 보통�가 암묵� 가� $0.64� 원천징수되어 취소되었으며, 공개 시장 매도� 없었습니�.

원천징수 � Forterre� 직접 소유 주식은 156,700�입니�. 또한 배우자가 간접 보유� 5,000�Armorica Partners, LLC� 통해 관리되� 32,500�� 보고하며, 이들 주식� 대� 의결� � 처분 권한� 행사합니�. 이번 제출은 일상적인 세금 원천징수 절차�, 내부� 소유 의도� 회사 전망� 변화를 의미하지 않습니다.

VolitionRx Ltd. (VNRX) � Dépôt du Formulaire 4

Le Directeur Commercial Gael Forterre a déclaré une seule transaction Code F le 1er août 2025, correspondant à des actions remises à la société pour couvrir les taxes lors du règlement de 6 690 unités d’actions restreintes reçues en lieu et place d’une rémunération en espèces. 2 766 actions ordinaires ont été retenues à un prix implicite de 0,64 $ puis annulées ; aucune vente sur le marché ouvert n’a eu lieu.

Après cette retenue, les avoirs de Forterre s’élèvent à 156 700 actions détenues directement. Il déclare également 5 000 actions détenues indirectement par son conjoint et 32 500 actions gérées via Armorica Partners, LLC, sur lesquelles il exerce un contrôle de vote et de disposition. Ce dépôt représente une retenue fiscale administrative courante et ne signale aucun changement dans l’intention de détention des initiés ni dans les perspectives de l’entreprise.

VolitionRx Ltd. (VNRX) � Form 4 Einreichung

Chief Commercial Officer Gael Forterre meldete am 1. August 2025 eine einzelne Code-F-Transaktion, bei der Aktien an das Unternehmen zurückgegeben wurden, um Steuern bei der Abwicklung von 6.690 eingeschränkten Aktieneinheiten zu begleichen, die anstelle von Barvergütung erhalten wurden. 2.766 Stammaktien wurden zu einem impliziten Preis von 0,64 $ einbehalten und somit storniert; ein Verkauf am offenen Markt fand nicht statt.

Nach der Einbehaltung hält Forterre 156.700 direkt besessene Aktien. Zudem berichtet er über 5.000 Aktien, die indirekt von seiner Ehefrau gehalten werden, sowie 32.500 Aktien, die über Armorica Partners, LLC verwaltet werden, über die er Stimm- und Verfügungsrechte ausübt. Die Einreichung stellt eine routinemäßige administrative Steuerabführung dar und signalisiert keine Änderung der Insider-Besitzabsicht oder der Unternehmensperspektive.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Forterre Gael

(Last) (First) (Middle)
1489 WEST WARM SPRINGS ROAD
SUITE 110

(Street)
HENDERSON NV 89014

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VOLITIONRX LTD [ VNRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/01/2025 F 2,766(1) D $0.64 156,700 D
Common Stock 5,000 I By Spouse
Common Stock 32,500 I By Armorica Partners, LLC(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 6,690 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.
2. These shares of common stock are managed by Armorica Partners, LLC (formerly Armori Capital Management, LLC) ("Armorica Partners"). Mr. Forterre is the managing director and sole shareholder of Armorica Partners and has voting and dispositive control over the shares held by Armorica Partners. Mr. Forterre disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Remarks:
/s/ Gael Forterre 08/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did VolitionRx (VNRX) insider Gael Forterre report on Form 4?

2,766 shares were withheld and cancelled on 1 Aug 2025 to cover taxes on vested RSUs; no shares were sold on the market.

How many VolitionRx shares does Forterre own after the transaction?

He holds 156,700 shares directly, plus 5,000 via spouse and 32,500 through Armorica Partners.

What price was used for the tax-withholding share cancellation?

The shares were valued at $0.64 each according to the Form 4 filing.

Does the filing indicate an open-market sale by the insider?

No. The Code F transaction reflects shares surrendered for tax withholding; no market sale occurred.

Why were 2,766 shares withheld from Forterre’s RSU vesting?

The shares satisfied tax obligations arising from the settlement of 6,690 restricted stock units awarded in lieu of cash compensation.
Volitionrx

NYSE:VNRX

VNRX Rankings

VNRX Latest News

VNRX Latest SEC Filings

VNRX Stock Data

66.55M
83.43M
18.4%
20.49%
0.35%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
United States
HENDERSON